Dyax Corporation

Protein Engineering Corporation

Other

Takeda Pharmaceutical Company Limited

Bracco Suisse Sa

Genex Corporation

Enzon Labs Inc.

Syntonix Pharmaceuticals, Inc.

Enzon, Inc.

Morphosys Ag

Biogen Hemophilia Inc.

Robert Charles Ladner

Arthur Charles Ley

William Markland

Rachel B Kent

Anthony Williams

Sonia Kosow Guterman

Bruce Lindsay Roberts

Shirish Hirani

Daniel T Dransfield

Kristin L Rookey

Rene Hoet

Clive R Wood

Hendricus Renerus Jacobus Mattheus Hoogenboom

Daniel J Sexton

Robert E Bird

Karl D Hardman

Horacio Gabriel Nastri

Edward Hirsch Cohen

Palaniappa Nanjappan

Jurgen Mullberg

Shannon Hogan

Henry Blair

Thomas Beck

John Moore Maclennan

Alan J Bitonti

Kevin McDonnell

Jennifer A Dumont

Isaac J Rondon

Christopher TenHoor

Arumugam Muruganandam

Laetitia Devy

Maria Henderikx

Luigi Bergamaschini

Henk Pieters

Thomas Cushman Ransohoff

Liming Liu

Philippe Bussat

Rolf E Swenson

Kondareddiar Ramalingam

Feng Yan

Adrian D Nunn

Karen E Linder

Edmund R Marinelli

Radhakrishna K Pillai

Michael W Pantoliano

Andrew Nixon

Bo Song

Malini Viswanathan

Sibylle Pochon

Mathew A Von Wronski

Ajay Shrivastava

Hong Fan

Christophe Arbogast

Sudha Khurana

Henricus Renerus Jacobus Mattheus Hoogenboom

James Stattel

Willaim Markland

Maria Grazia De Simoni

Qi-Long Wu

James P Beltzer

James McGivney

Sonia Schoonbroodt

Tony J Fleming

Marilou Potter, Legal Representative

Sonia Kosow Gutterman

Christopher Jon Luneau

Maria Grazia Simoni

Mark Stochl

Hendricus R Hoogenboom

Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.

Libraries of genetic packages comprising novel HC CDR3 designs

Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs

Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.

Display library process

Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.

Prevention and reduction of blood loss

Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries

Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

Focused libraries of genetic packages

A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.

Peptides that specifically bind HGF receptor (cMet) and uses thereof

Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.

Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

Growing community of inventors

Ijamsville, MD, United States of America

Robert Charles Ladner